GLP-1 drugs, which have been seen as a potential solution for obesity, are becoming less accessible as private health insurance plans reduce coverage. These medications can cost hundreds of dollars per month, making affordability a significant issue for many individuals. In 2026, approximately two-thirds of private employer plans were covering GLP-1 medications for weight loss, but recent trends show a decline in this coverage. Medicare introduced a $50-per-month prescription program for GLP-1 drugs, but private plans are now reconsidering their support.
The reduction in coverage is attributed to the structural flaws in the American healthcare system, where insurance is often tied to employment. As job turnover increases, employers have less incentive to invest in long-term health solutions. Dan Sacks, a healthcare economist at the University of Wisconsin-Madison, noted that employers and insurers may prioritize short-term cost savings over long-term health benefits, which could ultimately lead to higher costs for the healthcare system as a whole.
Recent surveys indicate that at least 10% of employer plans that currently cover GLP-1s for weight loss are likely to discontinue coverage in 2027. Companies such as PepsiCo, Starbucks, and Lowe's are reportedly reducing their coverage due to the high costs associated with these drugs, which can exceed $600 for a 30-day supply. The increased demand for GLP-1 medications, which are used by a significant portion of the population with obesity, is causing financial strain on employer-sponsored insurance plans.
Economists have expressed surprise at the sudden reversal in coverage, as many believed that employers recognized the long-term benefits of these medications. However, the short-term costs of covering GLP-1 drugs often outweigh the perceived long-term benefits from the employer's perspective. Studies have shown that covering GLP-1s can significantly increase employee health costs without immediate reductions in obesity-related medical events.
The future of GLP-1 coverage remains uncertain, as the market for these drugs is not expected to become more affordable in the near term. Generic versions of semaglutide are not anticipated to be available until at least 2031. The government’s ability to negotiate drug prices currently only applies to Medicare, leaving many private plans without similar support. The ongoing challenge highlights the need for a reevaluation of the U.S. healthcare system, which often prioritizes short-term financial considerations over long-term health outcomes.